Results 81 to 90 of about 13,526 (188)
Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease
PharmaceuticalsNintedanib, an intracellular inhibitor that targets multiple tyrosine kinase, is an important drug for the treatment of pulmonary fibrosis. Until now, no studies have been published reporting the nintedanib tolerability or its efficacy in patients with ...
Marta Maggisano +11 more
doaj +1 more source
Nintedanib regulates miR-23b-3p/TGFBR2 axis and competitively binds to TGFBR2 protein, inhibiting EMT process in human pterygium cells [PDF]
International Journal of OphthalmologyAIM: To investigate the effects of nintedanib on epithelial-mesenchymal transition (EMT) in cells derived from pterygium, aiming to explore its potential as a pharmacological intervention for pterygium treatment.
Ke-Ke Zhang +5 more
doaj +1 more source
, 2019 Abe M, Tsushima K, Sakayori M, et al. Drug Des Devel Ther. 2018;12:3369–3375.On page 3372, last paragraph of “Results” section should read from “In Severe Group, patients who were able to continue nintedanib for ...
Terada J +6 more
core
Post‐Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management
MedComm, Volume 7, Issue 10, October 2026.A comprehensive review on post‐tuberculosis lung disease (PTLD) addresses the epidemiology, pathogenesis, clinical phenotypes and management, risk factors, prevention and systems approach, and future directions. This review provides standardized definitions, mechanistic insights and biomarkers of PTLD development, and clinical strategies for PTLD ...
Radha Gopalaswamy, Selvakumar Subbian
wiley +1 more source
MedComm, Volume 7, Issue 10, October 2026.The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley +1 more source
Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: Results of the INJOURNEY trial [PDF]
, 2018 Measurements and Main Results: On-treatment gastrointestinal adverse events were reported in 37 of 53 patients (69.8%) treated with nintedanib with add-on pirfenidone and 27 of 51 patients (52.9%) treated with nintedanib alone.
INJOURNEY Trial Investigators
core +2 more sources
Journal of Peptide Science, Volume 32, Issue 10, October 2026.Reversing the peptide backbone sequence of novel tryptophyl‐dipeptides uncovers profound changes in synthetic accessibility and antineoplastic profiles against human solid tumors. Phenotypic screening identifies a conformationally restricted lead architecture that achieves sub‐micromolar growth inhibition, confirming sequence topology as a critical ...
J. Benamer Díaz +3 more
wiley +1 more source
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
ERJ Open Research, 2019 We conducted a post hoc analysis to assess the potential impact of GAP (gender, age, physiology) stage on the treatment effect of nintedanib in patients with idiopathic pulmonary fibrosis.
Christopher J. Ryerson +6 more
doaj +1 more source
PLoS ONE, 2020 BackgroundNintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear.
Satoru Senoo +20 more
doaj +1 more source
Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis [PDF]
Background: Nintedanib is used to treat both idiopathic and progressive pulmonary fibrosis (IPF/PPF). Evidence of both an exposure-response relationship and an exposure-toxicity relationship has been found, suggesting the potential value of therapeutic ...
Koolen, S. L.W. +9 more
core +1 more source